Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication

被引：2
作者：
Ma, Yanlei [1 ]
Qin, Huanlong [1 ]
Zheng, Qi [1 ]
Wang, Yu [1 ]
Wang, Zhiguo [1 ]
Yang, Zhe [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 6, Dept Surg, Shanghai 200233, Peoples R China
来源：
MEDICAL ONCOLOGY | 2010年 / 27卷 / 04期
关键词：
Neoadjuvant chemotherapy; Nonresectable advanced gastric cancer; Docetaxel; Cisplatin; Fluorouracil; Leucovorin; PHASE-II; PLUS FLUOROURACIL; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; D2; GASTRECTOMY; CARCINOMA; ADENOCARCINOMA; SURVIVAL; STRATEGIES; ETOPOSIDE;
D O I：
10.1007/s12032-009-9340-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of this study was to evaluate the efficacy and toxicity of docetaxel (TAX), cisplatin (CDDP), and fluorouracil (5-FU) plus leucovorin (CF) as the neoadjuvant chemotherapy (NACT) regimens in the treatment of nonresectable advanced gastric cancer. Twelve patients with nonresectable advanced gastric cancer were treated with NACT regimens consisted of docetaxel, cisplatin, fluorouracil, plus leucovorin before operation. Nine of the 12 patients were downstaged and 8 were radically operated after the end of the NACT. The overall response rate was 75% with 8.3% complete response and 66.7% partial response, and the ascites disappeared in 63.6%. The most common toxicities were bone marrow suppression, nausea, vomiting, alopecia, and heptoses. The toxicities were recoverable after symptomatic treatment. The results confirmed that the combination of docetaxel, cisplatin, fluorouracil plus leucovorin (CF) is a very effective and well-tolerated regimen as NACT for the patients with nonresectable advanced gastric cancer.
引用
收藏
页码：1089 / 1095
页数：7
相关论文
共 50 条
  • [21] Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
    Quintero-Aldana, G.
    Jorge, M.
    Grande, C.
    Salgado, M.
    Gallardo, E.
    Varela, S.
    Lopez, C.
    Villanueva, M. J.
    Fernandez, A.
    Alvarez, E.
    Gonzalez, P.
    Castellanos, J.
    Casal, J.
    Lopez, R.
    Campos Balea, B.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 731 - 737
  • [22] Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer
    Kinro Sasaki
    Shinichi Onodera
    Kichiro Otsuka
    Hitoshi Satomura
    Eigo Kurayama
    Tsukasa Kubo
    Masakazu Takahashi
    Jun Ito
    Masanobu Nakajima
    Satoru Yamaguchi
    Kazuhito Miyachi
    Hiroyuki Kato
    [J]. Medical Oncology, 2017, 34
  • [23] Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer
    Popov, I.
    Radosevic-Jelic, L.
    Jezdic, S.
    Milovic, M.
    Borojevic, N.
    Stojanovic, S.
    Stankovic, V.
    Josifovski, T.
    Kezic, I.
    [J]. JOURNAL OF BUON, 2008, 13 (04): : 505 - 511
  • [24] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer
    Emi, Manabu
    Hihara, Jun
    Hamai, Yoichi
    Aoki, Yoshiro
    Okada, Morihito
    Kenjo, Masahiro
    Murakami, Yuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1499 - 1505
  • [25] Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
    Yu, Deguo
    Wang, Zhenfeng
    He, Tingbang
    Yang, Lijun
    [J]. FRONTIERS IN SURGERY, 2022, 9
  • [26] Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma
    Ming gao Guo
    Qi Zheng
    Jian zhong Di
    Zhe Yang
    [J]. World Journal of Surgical Oncology, 12
  • [27] Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer
    Maeda, Osamu
    Furune, Satoshi
    Kanda, Mitsuro
    Miyata, Kazushi
    Shimizu, Dai
    Sugita, Shizuki
    Nishida, Kazuki
    Ando, Masahiko
    Kodera, Yasuhiro
    Ando, Yuichi
    [J]. CANCER MEDICINE, 2024, 13 (02):
  • [28] Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus
    Ojima, Toshiyasu
    Nakamori, Mikihito
    Nakamura, Masaki
    Katsuda, Masahiro
    Hayata, Keiji
    Kato, Tomoya
    Kitadani, Junya
    Tabata, Hirotaka
    Takeuchi, Akihiro
    Iwahashi, Makoto
    Yamaue, Hiroki
    [J]. ANTICANCER RESEARCH, 2016, 36 (02) : 829 - 834
  • [29] Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil
    Mohri, Junichi
    Katada, Chikatoshi
    Ueda, Marie
    Sugawara, Mitsuhiro
    Yamashita, Keishi
    Moriya, Hiromitsu
    Komori, Shouko
    Hayakawa, Kazushige
    Koizumi, Wasaburo
    Atsuda, Koichiro
    [J]. JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2018, 6 (01) : 32 - 37
  • [30] A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer
    Li, Maoquan
    Zhang, Jiaxing
    Wang, Daoyuan
    Zhong, Baoliang
    Tucker, Steven
    Lu, Chenhui
    Cheng, Jie
    Ca, Chuanwu
    Xu, Jiahua
    Xu, Jichong
    Pan, Hui
    [J]. ANTI-CANCER DRUGS, 2009, 20 (10) : 941 - 945
12345